8 research outputs found
Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors
10.3390/cancers9080109Cancers9810
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
10.1002/cam4.985Cancer Medicine61173-18
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. pCR following neoadjuvant chemotherapy was defined as 1) no residual invasive tumor cells in the breast (ypT0/is) and 2) no residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is ypN0). Association between pCR and clinicopathologic characteristics and treatment were evaluated using chi-square test and multivariable logistic regression. Kaplan–Meier analysis and log-rank test, stratified by other prognostic factors, were conducted to compare overall survival between patients who achieved pCR and patients who did not. Overall, 4.4% of nonmetastatic patients received neoadjuvant chemotherapy. The median age of preoperatively treated patients was 50 years. pCR rates were 18.1% (pCR ypT0/is) and 14.4% (pCR ypT0/is ypN0), respectively. pCR rate was the highest among women who had higher grade, smaller size, estrogen receptor negative, human epidermal growth factor receptor 2-positive disease or receiving taxane-based neoadjuvant chemotherapy. Patients who achieved pCR had better overall survival than those who did not. In subgroup analysis, the survival advantage was only significant among women with estrogen receptor-negative tumors. Patients with poor prognostic profile are more likely to achieve pCR and particularly when receiving taxane-containing chemotherapy. pCR is a significant prognostic factor for overall survival especially in estrogen receptor-negative breast cancers
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
10.1186/s12885-020-07616-4BMC Cancer201111
Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: A pilot study
10.3389/fonc.2016.00274Frontiers in Oncology6JAN27
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
10.1186/s12967-015-0405-4Journal of Translational Medicine1315
Low Levels of NDRG1 in nerve tissue are predictive of severe paclitaxel-induced neuropathy
10.1371/journal.pone.0164319PLoS ONE1110e016431